s e n hyperimmune i c a gllobulobulinsigim v flu g i … · 2015. 10. 23. · the products you s c...

the products youSC

IGFLUVACCINE

PRODUCTCOAGULATIO

ALBUMI LASMA PROTEIN/PLASMA PROTEIN FRACTI

IVIGHYPERIMMUNELOBULGLOBULINSVACCINES

IGIMHYPERIMMUNELOBULGLOBULINSVACCINES

CIG COA

PRO

when yo

TSON

TION

G

M

SC ALBUMI

IGI

VA

CCIN

ESHYPEGLO

RPROTALBU

N/P

PRO

24h

enterprises.com .FFF(800) 843-7477 | www om 102TCO 5

ACTURER

FFAMAN

U

om tampering or misis never in question frans th his meTce.another distributor or sour

om the oducts frchase pr we only pur,At FFFchasingurP

8Critical S

shandling.oducts our pr he integrity of

om never frr – e manufactur

Steps

and supported with bace variatioaturto temper

ansport e and tre storWagetorS

ators in the event oup gener ck molled,e contraturemperT ons.

otein compounds th viable pr

s. power los ofed 24/7, monitor

e sensitive at ar

ate efrigerragingpack

Specia

oducts.ed prozen and ecautions for fra prxtr taking eg,

agingackalty P

oducts in challenging pr

active AlloInter

educes Ret conditions. g mark

ocation

potential for

CONT

Hyperim Immune

t oagulaCCustome

ce esourR

ENTS

. . . . . . . . . . . . . . . . . . . .mune Globulins.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Globulins

.. . . . . . . . . . . . . . . . . . . . . . . .oducts rtion P... . . . . . . . . . . . . . . . . . . . . . . . . . . .ter Suppor

... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .es

Onc10... ... . . . . . . . . . . . . . . . . . .8–9... . . . . . . . . . . . . . . . . . . .6–8... . . . . . . . . . . . . . . . . . . .

5.. . . . . . . . . . . . . . . . . . . . . . . . .4.. . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .cology

... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

14–15... . . . . . . . . . . . . . . . . . . . . . . . . . . 1413... . . . . . . . . . . . . . . . . . . . . . . . . . . . .12... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .11... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

yp

11... . . . . . . . . . . . . . .

gy

15... . . . . . . . . . . . . . . . . .

http://www.fffenterprises.com/company/guaranteed-channel-integrity.html

seco to d add

e WDe

nChannel ITo Guaran

ondary distribution channel.om enterin oducts frevent pr do everything in our power to pr

It is our commitment ceptions.xe no ee makWs on the license.esdr and only sued license, deliver only to facilities with a state-is

elivery

™yntegrit nteed

ng a itment

y to the

allows time-s Monitoring a

e pr sensitive delivery to ensura eme wextr and adjusting for e

.oduct integrity rather conditions

chased pharmaceuticals puree of

to e

omer information,

e asily verify online the pedigr

. drug we supplyfor every vial of

matched to custo ,oduct lot numberach pre

less safety record.strated by our flawis demontical supply chainarmaceuent to a secure phOur commitm

Since 1988S er 27 counterfeit-free yearsOv

http://www.fffenterprises.com/company/guaranteed-channel-integrity.html

Resourc

m

pp y

in T

Subscribe and view our online

ends Quarterly MagrTBioSupply

etplace.marknformation for the biopharmaceutical

ce for newhe definitive sourT

ces

view our online

azine asonal Flu

omplimentary posters in English, maceutical

ends and tr ws,

accination cli

Se

nd Mandarin C

der or download online

oster u P

Or inics.omote flu n to help plan and pr Spanish ry posters in English,

e

pg R

Quarterly

Subscribe and view our online

IG Living! Magazine

ovidersprglobulin patients and their he

sful livin ces for succesesourR

T.BSedition at www

.com

w our online e althcar e

ng for immune

Flu

en

i ti

ac Myths & F

fhighlighting prDispelling the myths about the dise

.FFFt www

terprises.com

d li t

eochurts Br

Oevention and the benefits g pr

ase and he myths about the dise

e

prAw

p.IGLiving.com

oviding insight into the comple

teeNewsletends rBioSupply T

rd-winning bimonthly war

edition at www Subscribe and view our online oviders.pr

m

xities of

er

completer y eNewslet

w our online

oe

ent

individual customer gr

ommunication AlertseC

fommunic C

.FFFwww vaccinatioof

terprises.com

oups and patient

tion Alerts

al customer gred to meet the needs cations tailor

der online at Or on.

ence Cha eferRs complim FFF’

Su th p

• Immune Glob

ence Charts

.F

asonal Infl • See highly

eferoduct RrP

rts aroductr entary P

ubscribe online at wwwhe specialty pharmaceuti

g g

enterprises.com

bulinaccine V uenza

FFFetplace. cals mark

p

wo

eimburseme

ent.FFFwwwganizationr

IVIG R

ind F

alculator

terprises.com

ent

Subscribe online atns.p p g

ent C

d the curr

d Or

ative pcomparvalued educati

ence Cha eferR

actor VIIIF• Anti-Inhibitor •

• Hyperimmun Immune Glob

enterprises.FFFer charts online at www

oduct information. rces foresour ional r

e highly rts ar

VIIa & IXactor r F ne Globulin bulin

s.com

at weim r

enterprises.com.FFF wwwates for IVIG mbursement r

O ORDER TO

ax (800) 418- (800) 843-7477 | F

enterprises.com | www.FFF -4333 | www

fenterprises.comfffenterprises.com.fffaccine.com | biosupply.MyFluVVaccine.com | biosupplym | www4

http://www.bstquarterly.com/http://www.igliving.com/http://www.fffenterprises.com/resources/biosupply-trends-enewsletter.htmlhttp://www.fffenterprises.com/resources/reference-charts.htmlhttp://www.fffenterprises.com/resources/seasonal-flu-posters.htmlhttp://www.fffenterprises.com/resources/flu-myths-facts-brochure.htmlhttp://www.fffenterprises.com/resources/ecommunications.htmlhttp://www.fffenterprises.com/resources/ivig-reimbursement-calculator.aspxhttp://www.fffenterprises.com/http://www.myfluvaccine.com/https://biosupply.fffenterprises.com/product-catalog

Custom

From our in house teams o

e to Suppoe HerArow! CustomeWOur

upporter S

ou.Yoofessionals r P™ear C

of cu

Yt rrter C

r

From our in-house teams of curepresentatives, advisors and

managers, there is always a rededicated expert to take care

Emergency ordering and shippin

On-call pharmacist™ fo

Lot-Track™

BioSupply™ online ordering and

Specialty publications for current and inventory news

Expert advisors

Patient advocates

24h

f

(800) 843-7477FFF Enterprises.

ovidevery drug prdosing questions about

odanswer your prtise xperhave the e

Our on-call pharm

(800) 843-7477outcomes.

tient oving paimpre and fective carcost-efffective car

,apyy,neous infusion theravenous and subcuta- intr

about the principles ofwill answer your questions Our infusion specialists

Advisor LinePharmacy

Advisor LineInfusion

Nationwide, robust sales force of

eimbursement Our rmacists Advisor Line

eimbursementR

(800) 843-7477eimbursement.r

biopharmaceutical ofxities the compleough and guide you thr

esolve your questions rady to ee rspecialists ar

ed by about uct or e to

fenterprises.comfffenterprises.com.fffaccine.com | biosupply.MyFluVVaccine.com | biosupplym | www

enterprises.com | www.FFFax (800) 418-4333 | www (800) 843-7477 | FO ORDER TO 5

http://www.fffenterprises.com/site/company-contacts.htmlhttp://www.fffenterprises.com/site/company-contacts.htmlhttp://www.fffenterprises.com/http://www.myfluvaccine.com/https://biosupply.fffenterprises.com/product-catalog

TO ORDER (800) 843-7477 | Fax (800) 418-4333 | www.FFFenterprises.com | www.MyFluVaccine.com | biosupply.fffenterprises.com

Product Size Manufacturer NDC# Code*

ANTI-INHIBITOR (HUMAN-PLASMA DERIVED)

FEIBA NF 500 IU VIAL W/BAXJECT II BAXALTA 64193-0423-02 J7198 1000 IU VIAL W/BAXJECT II 64193-0424-02 J7198 2500 IU VIAL W/BAXJECT II 64193-0425-02 J7198

FACTOR VIIa (RECOMBINANT)

NOVOSEVEN RT 1000 MCG VIAL NOVO NORDISK 00169-7201-01 J7189 WITH MIXPRO 2000 MCG VIAL 00169-7202-01 J7189 5000 MCG VIAL 00169-7205-01 J7189 8000 MCG VIAL 00169-7208-01 J7189

FACTOR VIII (HUMAN–PLASMA DERIVED)

KOATE DVI 250 IU VIAL KEDRION 76125-0250-20 J7190 500 IU VIAL 76125-0500-30 J7190 1000 IU VIAL 76125-0672-50 J7190

VON WILLEBRAND FACTOR / FACTOR VIII COMPLEX (HUMAN-PLASMA DERIVED)

ALPHANATE 250 IU VIAL+ GRIFOLS 68516-4601-01 J7186 500 IU VIAL+ 68516-4602-01 J7186 1000 IU VIAL+ 68516-4603-02 J7186 1500 IU VIAL+ 68516-4604-02 J7186 HUMATE-P 500 RCOF+ VIAL CSL BEHRING 63833-0615-02 J7187 1000 RCOF+ VIAL 63833-0616-02 J7187 2000 RCOF+ VIAL 63833-0617-02 J7187

WILATE 500 IU VIAL+ OCTAPHARMA 67467-0182-01 J7183 1000 IU VIAL+ 67467-0182-02 J7183

FACTOR VIII (RECOMBINANT)

ADVATE 2 ML 250 IU VIAL BAXALTA 00944-2921-02 J7192 500 IU VIAL 00944-2922-02 J7192 1000 IU VIAL 00944-2923-02 J7192 1500 IU VIAL 00944-2924-02 J7192

ADVATE 5 ML 2000 IU VIAL BAXALTA 00944-2964-10 J7192 3000 IU VIAL 00944-2965-10 J7192 4000 IU VIAL 00944-2948-10 J7192

ELOCTATE 250 IU VIAL BIOGEN IDEC 64406-0801-01 J7199 500 IU VIAL 64406-0802-01 J7199 750 IU VIAL 64406-0803-01 J7199 1000 IU VIAL 64406-0804-01 J7199 1500 IU VIAL 64406-0805-01 J7199 2000 IU VIAL 64406-0806-01 J7199 3000 IU VIAL 64406-0807-01 J7199

HELIXATE FS 250 IU VIAL CSL BEHRING 00053-8131-02 J7192 500 IU VIAL 00053-8132-02 J7192 1000 IU VIAL 00053-8133-02 J7192 2000 IU VIAL 00053-8134-02 J7192 3000 IU VIAL 00053-8135-02 J7192

KOGENATE FS 250 IU VIAL W/BIOSET BAYER 00026-3792-20 J7192 500 IU VIAL W/BIOSET 00026-3793-30 J7192 1000 IU VIAL W/BIOSET 00026-3795-50 J7192 2000 IU VIAL W/BIOSET 00026-3796-60 J7192

Coagulation Products

Continued*All codes should be verified between the provider and the payer.+Call (800) 843-7477 or check ordering screen for RCo values.

VIPc

VIPc340B

VIPc340B

VIPc340B

VIPc340B

VIPc340B

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc Verified Inventory Program–Consignment eligible. Public Health Services 340B pricing available.340B

6

http://www.fffenterprises.com/http://www.myfluvaccine.com/https://biosupply.fffenterprises.com/product-catalog

Continued


FACTOR VIII (RECOMBINANT) CONTINUED KOGENATE FS VIAL ADAPTER 250 IU VIAL W/VIAL ADAPTER BAYER 00026-3782-25 J7192 500 IU VIAL W/VIAL ADAPTER 00026-3783-35 J7192 1000 IU VIAL W/VIAL ADAPTER 00026-3785-55 J7192 2000 IU VIAL W/VIAL ADAPTER 00026-3786-65 J7192

NOVOEIGHT 250 IU VIAL NOVO NORDISK 00169-7825-01 J7182 500 IU VIAL 00169-7850-01 J7182 1500 IU VIAL 00169-7815-01 J7182 2000 IU VIAL 00169-7820-01 J7182 3000 IU VIAL 00169-7830-01 J7182

RECOMBINATE 250 IU VIAL BAXALTA 00944-2841-10 J7192 500 IU VIAL 00944-2842-10 J7192 1000 IU VIAL 00944-2843-10 J7192 1500 IU VIAL 00944-2844-10 J7192 2000 IU VIAL 00944-2845-10 J7192

XYNTHA 250 IU VIAL PFIZER 58394-0012-01 J7185 500 IU VIAL 58394-0013-01 J7185 1000 IU VIAL 58394-0014-01 J7185 2000 IU VIAL 58394-0015-01 J7185 3000 IU VIAL 58394-0016-03 J7185

XYNTHA SOLOFUSE 250 IU/4ML DCS PFIZER 58394-0022-03 J7185 500 IU/4ML DCS 58394-0023-03 J7185 1000 IU/4ML DCS 58394-0024-03 J7185 2000 IU/4ML DCS 58394-0025-03 J7185

FACTOR VIII (MONOCLONAL PURIFIED)

HEMOFIL M 250 IU VIAL BAXALTA 00944-3940-02 J7190 500 IU VIAL 00944-3942-02 J7190 1000 IU VIAL 00944-3944-02 J7190 1500 IU VIAL 09444-3946-02 J7190

MONOCLATE-P 1000 IU VIAL CSL BEHRING 00053-7656-04 J7190 1500 IU VIAL 00053-7656-05 J7190

FACTOR IX (HUMAN–PLASMA DERIVED)

ALPHANINE SD 500 IU VIAL GRIFOLS 68516-3601-02 J7193 1000 IU VIAL 68516-3602-02 J7193 1500 IU VIAL 68516-3603-03 J7193

BEBULIN 500 IU VIAL BAXALTA 06419-3445-02 J7194

FACTOR IX (MONOCLONAL PURIFIED)

MONONINE 1000 IU VIAL CSL BEHRING 00053-6223-02 J7193

FACTOR IX (RECOMBINANT)

ALPROLIX 500 IU VIAL BIOGEN IDEC 64406-0911-01 J7199 1000 IU VIAL 64406-0922-01 J7199 2000 IU VIAL 64406-0933-01 J7199 3000 IU VIAL 64406-0944-01 J7199

BENEFIX RT 250 IU VIAL PFIZER 58394-0633-03 J7195 500 IU VIAL 58394-0634-03 J7195 1000 IU VIAL 58394-0635-03 J7195 2000 IU VIAL 58394-0636-03 J7195 3000 IU VIAL 58394-0637-03 J7195

RIXUBIS 250 IU VIAL BAXALTA 00944-3026-02 J7195 500 IU VIAL 00944-3028-02 J7195 1000 IU VIAL 00944-3030-02 J7195 2000 IU VIAL 00944-3032-02 J7195 3000 IU VIAL 00944-3034-02 J7195

Coagulation Products

*All codes should be verified between the provider and the payer.


VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc340B

VIPc340B

VIPc340B


7

COAGUALATIONIM

MUNE

GLOBULINSHYPERIM

MUNES

INFLUENZA VACCINES& ANCILLARIES

OTHERVACCINES

ALBUMIN / PLASM

APROTEIN FRACTION

SPECIALTY& ONCOLOGY

GENERIC INJECTABLES& SURGICAL SEALANTS




IMMUNE GLOBULINS SUBCUTANEOUS (SCIG)

HIZENTRA 1 GM VIAL CSL BEHRING 44206-0451-01 J1559 2 GM VIAL 44206-0452-02 J1559 4 GM VIAL 44206-0454-04 J1559 10 GM VIAL 44206-0455-10 J1559

HYQVIA 2.5 GM VIAL BAXALTA 00944-2510-02 5 GM VIAL 00944-2511-02 10 GM VIAL 00944-2512-02 20 GM VIAL 00944-2513-02 30 GM VIAL 00944-2514-02

GAMUNEX-C 1 GM VIAL GRIFOLS 13533-0800-12 J1561 2.5 GM VIAL 13533-0800-15 J1561 5 GM VIAL 13533-0800-20 J1561 10 GM VIAL 13533-0800-71 J1561 20 GM VIAL 13533-0800-24 J1561 40 GM VIAL 13533-0800-40 J1561

GAMMAGARD LIQUID 1 GM VIAL BAXALTA 00944-2700-02 J1569 2.5 GM VIAL 00944-2700-03 J1569 5 GM VIAL 00944-2700-04 J1569 10 GM VIAL 00944-2700-05 J1569 20 GM VIAL 00944-2700-06 J1569 30 GM VIAL 00944-2700-07 J1569

GAMMAKED 1 GM VIAL KEDRION 76125-0900-01 J1561 2.5 GM VIAL 76125-0900-25 J1561 5 GM VIAL 76125-0900-50 J1561 10 GM VIAL 76125-0900-10 J1561 20 GM VIAL 76125-0900-20 J1561

OTHER COAGULATION PRODUCTS

KCENTRA 500 IU VIAL CSL BEHRING 63833-0386-02 J3590 1000 IU VIAL 63833-0387-02 J3590

PROFILNINE SD 500 IU VIAL GRIFOLS 68516-3201-01 J7194 1000 IU VIAL 68516-3202-02 J7194 1500 IU VIAL 68516-3203-02 J7194

RIASTAP 1000 MG VIAL CSL BEHRING 63833-0891-51 J1680

STIMATE NASAL SPRAY 1.5 ML CSL BEHRING 00053-6871-00 J3490

Immune Globulins Subcutaneous (SCIG)


IMMUNE GLOBULIN INTRAMUSCULAR (IGIM) GAMASTAN S/D 2 ML VIAL GRIFOLS 13533-0635-04 J1460 10 ML VIAL 13533-0635-12 J1460

Immune Globulin Intramuscular (IGIM)


**Call Baxalta Reimbursement at (888) 229-8379 for the most up-to-date billing code.

J3490 or J3590** J3490 or J3590** J3490 or J3590** J3490 or J3590** J3490 or J3590**


Coagulation Products (CONTINUED)

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc340B

VIPc340B


8


9TO ORDER (800) 843-7477 | Fax (800) 418-4333 | www.FFFenterprises.com | www.MyFluVaccine.com | biosupply.fffenterprises.com


IMMUNE GLOBULINS (HUMAN) LYOPHILIZED

CARIMUNE NF 6 GM VIAL CSL BEHRING 44206-0417-06 J1566 12 GM VIAL 44206-0418-12 J1566

GAMMAGARD S/D 5 GM VIAL BAXALTA 00944-2656-03 J1566(IGA


ANTI-THYMOCYTE GLOBULIN

THYMOGLOBULIN 25 MG VIAL SANOFI AVENTIS 58468-0080-01 J7511

BOTULISM IGIV (HUMAN) (BIG-IV)

BABYBIG 100 MG VIAL CALIFORNIA DEPT. OF HEALTH 68403-1100-06 —

CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN)

CYTOGAM 2.5 GM VIAL CSL BEHRING 44206-0532-11 J0850

HEPATITIS B IMMUNE GLOBULIN

HEPAGAM B 1 ML VIAL EMERGENT BIOSOLUTIONS 53270-0052-01 J1571 or J1573 5 ML VIAL 53270-0051-01 J1571 or J1573

HYPERHEP B S/D 0.5 ML SYRINGE GRIFOLS 13533-0636-03 90371 1 ML SYRINGE 13533-0636-02 90371 5 ML VIAL 13533-0636-05 90371

NABI-HB 1 ML SDV BIOTEST PHARMACEUTICALS 59730-4202-01 90371 5 ML SDV 59730-4203-01 90371

RABIES IMMUNE GLOBULIN

HYPERRAB S/D 2 ML 150 IU/ML VIAL GRIFOLS 13533-0618-02 90375 10 ML 150 IU/ML VIAL 13533-0618-10 90375

RHO(D) IMMUNE GLOBULIN

HYPERRHO S/D 50 MCG/0.17 ML SYRINGE GRIFOLS 13533-0661-06 J2788 300 MCG 1 ML SYRINGE 13533-0631-02 J2790

MICRHOGAM 50 MCG 1 ML SYRINGE KEDRION 00562-7806-01 J2788 50 MCG 1 ML SYRINGE/5-PK 00562-7806-05 J2788 50 MCG 1 ML SYRINGE/25-PK 00562-7806-25 J2788

RHOGAM 300 MCG 1 ML SYRINGE KEDRION 00562-7805-01 J2790 300 MCG 1 ML SYRINGE/5-PK 00562-7805-05 J2790 300 MCG 1 ML SYRINGE/25-PK 00562-7805-25 J2790

RHOPHYLAC 300 MCG SYRINGE CSL BEHRING 44206-0300-01 J2791 300 MCG SYRINGE/10-PK 44206-0300-10 J2791

WINRHO SDF 1500 IU 300 MCG VIAL EMERGENT BIOSOLUTIONS 53270-3300-01 J2792 2500 IU 500 MCG VIAL 53270-3500-01 J2792 5000 IU 1000 MCG VIAL 53270-3100-01 J2792 15,000 IU 3000 MCG VIAL 53270-3000-01 J2792

TETANUS IMMUNE GLOBULIN

HYPERTET S/D 250 UNIT SYRINGE GRIFOLS 13533-0634-02 J1670

VARICELLA ZOSTER IMMUNE GLOBULIN

VARIZIG LIQUID 125 UNIT VIAL EMERGENT BIOSOLUTIONS 53270-0126-02 90396

Hyperimmune Globulins



VIPc

VIPc

VIPc

VIPc340B

VIPc340B

VIPc340B

VIPc340B

VIPc340B

VIPc340B

VIPc340B

VIPc340B

VIPc340B


VIPc340B

10


11


INFLUENZA VACCINES 2015-16 FLUVIRIN 5 ML 10 DS VIAL NOVARTIS 66521-0118-10 90658/Q2037 0.5 ML PFS 66521-0118-02 90656 FLUCELVAX 0.5 ML PFS NOVARTIS 62577-0614-01 90661FLUZONE 5 ML 10 DS VIAL SANOFI PASTEUR 49281-0396-15 90657/90658/Q2038FLUZONE QUADRIVALENT 5 ML 10 DS VIAL SANOFI PASTEUR 49281-0623-15 90687/90688 0.25 ML PFS 49281-0515-25 90685 0.5 ML PFS 49281-0415-50 90686 0.5 ML SDV 49281-0415-10 90686FLUZONE HIGH DOSE 0.5 ML PFS SANOFI PASTEUR 49281-0397-65 90662FLUZONE INTRADERMAL QUADRIVALENT 0.1 ML PFS SANOFI PASTEUR 49281-0708-40 90630AFLURIA 5 ML 10 DS VIAL BIOCSL 33332-0115-10 90658/Q2035 0.5 ML PFS 33332-0015-01 90656FLULAVAL QUADRIVALENT 5 ML 10 DS VIAL GSK 19515-0898-11 90688FLUARIX QUADRIVALENT 0.5 ML PFS GSK 58160-0903-52 90686FLUMIST QUADRIVALENT 0.2 ML INTRANASAL SPRAYER MEDIMMUNE 66019-0302-10 90672FLUBLOK 0.5 ML SDV PROTEIN SCIENCES 42874-0015-10 90673ANTIVIRALS RELENZA ROTADISK 5 MG GSK 00173-0681-01 —TAMIFLU 75 MG CAP 10-PK GENENTECH 00004-0800-85 J8499TAMIFLU ORAL SUSP 6 MG/ML GENENTECH 00004-0822-05 J8499

Product Description Manufacturer

PHARMAJET® NEEDLE-FREE INJECTION PRODUCTS (AVAILABLE ONLY FOR AFLURIA 5 ML 10 DS VIAL)

INJECTOR STARTER KIT SUPPLIES 500 FLU SHOTS AND INCLUDES: PHARMAJET - (1) PHARMAJET INJECTOR - (5) BOXES OF NEEDLE-FREE SYRINGES – 100/BOX - (1) BOX OF VIAL ADAPTERS – 100/BOX - (1) RESET STATION - (1) PRACTICE KIT

NEEDLE-FREE SYRINGES 100/BOX PHARMAJETVIAL ADAPTERS 100/BOX PHARMAJETPHARMAJET INJECTOR SPRING-OPERATED INJECTOR, REQUIRING PHARMAJET NO EXTERNAL POWER SOURCE

RESET STATION PREPARES THE INJECTOR FOR VACCINE ADMINISTRATION PHARMAJET

DISPOSABLE CONTAINERS SHARPS RECOVERY SYSTEM® 1-QUART, 1.5-QUART, 1-GALLON SHARPS COMPLIANCE 2-GALLON, 3-GALLON, 20-GALLON SHARPS RECOVERY SYSTEM® 5-GALLON SHARPS COMPLIANCEFOR USE WITH NON-SHARPS BIOHAZARD WASTE ONLY


TO ORDER (800) 843-7477 | Fax (800) 418-4333 | www.FFFenterprises.com | www.MyFluVaccine.com | biosupply.fffenterprises.com 11

COAGUALATIONIM

MUNE

GLOBULINSHYPERIM

MUNES


OTHERVACCINES

ALBUMIN / PLASM

APROTEIN FRACTION

SPECIALTY& ONCOLOGY



A 250 ML KEDRION 76125-0785-25 P9045 250 ML 76125-0790-25 P9045

A 250 ML CSL BEHRING 00053-7670-31 P9045 500 ML 00053-7670-32 P9045




A 250 ML GRIFOLS 68516-5214-01 P9045 500 ML 68516-5214-02 P9045

A 50 ML GRIFOLS 68516-5216-01 P9047 100 ML 68516-5216-02 P9047

A 250 ML OCTAPHARMA 67467-0623-02 P9045 250 ML 68209-0623-02 P9045 500 ML 68209-0623-03 P9045 500 ML 67467-0623-03 P9045

A 50 ML OCTAPHARMA 67467-0643-01 P9047 50 ML 68209-0643-01 P9047 100 ML 67467-0643-02 P9047 100 ML 68209-0643-02 P9047

B 500 ML BAXALTA 00944-0491-02 P9045

B 20 ML BAXALTA 00944-0490-01 P9046 50 ML 00944-0490-02 P9047

F 250 ML BAXALTA 00944-0495-05 P9047

F 50 ML BAXALTA 00944-0493-01 P9047 100 ML 00944-0493-02 P9047

K 50 ML KEDRION 76179-0025-01 P9047 100 ML 76179-0025-04 P9047

P 50 ML GRIFOLS 13533-0685-20 P9041 250 ML 13533-0685-25 P9045

P 20 ML GRIFOLS 13533-0684-16 P9046 50 ML 13533-0684-20 P9047 100 ML 13533-0684-71 —

P 50 ML GRIFOLS 13533-0690-02 — 250 ML 13533-0690-25 —

P 20 ML GRIFOLS 13533-0692-16 — 50 ML 13533-0692-20 — 100 ML 13533-0692-71 —

P 50 ML PPF GRIFOLS 13533-0613-20 P9043 250 ML PPF 13533-0613-25 P9043

| biosupply.fffenterprises.com

P

12


OTHER VACCINES

ACTHIB 10 MCG W/DILUENT SANOFI PASTEUR 49281-0545-05 90648ADACEL (TDAP) 5 PFS/BX SANOFI PASTEUR 49281-0400-15 90715 10 SDV/BX 49281-0400-10 90715DAPTACEL 10 SDV/BX SANOFI PASTEUR 49281-0286-10 90700DIPHTHERIA AND TETANUS TOXOID 10 SDV PF PEDS SANOFI PASTEUR 49281-0225-10 90714GARDASIL HPV 10 - 0.5 ML SDV MERCK 00006-4045-41 90649 0.5 ML VIAL 00006-4045-00 90649GARDASIL 9 HPV 10 - 0.5 ML SDV MERCK 00006-4119-03 90651 10 - 0.5 ML PFS 00006-4121-02 90651IMOVAX IM 1 SDV W/DILUENT SANOFI PASTEUR 49281-0250-51 90675IPOL POLIO VIRUS 5 ML MDV SANOFI PASTEUR 49281-0860-10 90713MENACTRA SDV/5-PK SANOFI PASTEUR 49281-0589-05 90734MENOMUNE SDV SANOFI PASTEUR 49281-0489-01 90733MMR II MEASLES MUMPS 0.5 ML SDV/10-PK MERCK 00006-4681-00 90707PEDVAX HIB 0.5 ML SDV/10-PK MERCK 00006-4897-00 90647PENTACEL SDV/5-PK SANOFI PASTEUR 49281-0510-05 90698PNEUMOVAX 23 0.5 ML SDV/10-PK MERCK 00006-4943-00 90732 2.5 ML VIAL 00006-4739-00 90732PREVNAR 13 PFS/10-PK PFIZER 00005-1971-02 90670PROQUAD 0.5 ML SDV/10-PK MERCK 00006-4999-00 90710RECOMBIVAX HB ADULT 10 MCG/SDV MERCK 00006-4995-00 90746 10 MCG VIAL/10-PK 00006-4995-41 90743/90746 10 MCG PFS/6-PK 00006-4094-09 90743/90746RECOMBIVAX HB PED/ADOLESC 5 MCG/6-PK PFS MERCK 00006-4093-09 90744 5 MCG/0.5 ML 10-PK 00006-4981-00 90744RECOMBIVAX HB DIALYSIS 40 MCG SDV MERCK 00006-4992-00 90740/90747ROTATEQ ROTAVIRUS 2 ML TUBES/10-PK MERCK 00006-4047-41 90680 2 ML TUBES/25-PK 00006-4047-20 90680 TENIVAC 10 SDV/BX SANOFI PASTEUR 49281-0215-10 90714 10 PFS/BX 49281-0215-15 90714TICE BCG 50 MG SDV MERCK 00052-0602-02 TBDTRUMENBA 0.5 ML SDV PF/5-PK PFIZER 00005-0100-05 90621 0.5 ML SDV PF/10-PK 00005-0100-10 90621TUBERSOL 1 ML VIAL 10 TEST SANOFI PASTEUR 49281-0752-21 86580 5 ML VIAL 50 TEST 49281-0752-22 86580TYPHIM VI TYPHOID 10 ML MDV SANOFI PASTEUR 49281-0790-20 90691 0.5 ML/PFS 49281-0790-51 90691VAQTA 50 U/1 ML PFS/6-PK MERCK 00006-4096-09 90632 25 U/1 ML PFS/6-PK 00006-4095-09 90633 25 U/0.5 ML SDV/10-PK 00006-4831-41 90633VARIVAX 0.5 ML SDV/10-PK MERCK 00006-4827-00 90716VIVOTIF BLISTER PK OF 4 CAPSULES PAXVAX 58337-0003-01 90690ZOSTAVAX SDV/10-PK MERCK 00006-4963-41 90736 SDV 00006-4963-00 90736

Other Vaccines



VIPc Verified Inventory Program–Consignment eligible.

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

VIPc

12


13


ALBUMIN / PLASMA PROTEIN FRACTION

ALBUKED 5% 250 ML KEDRION 76125-0785-25 P9045 250 ML 76125-0790-25 P9045

ALBUMINAR 5% 250 ML CSL BEHRING 00053-7670-31 P9045 500 ML 00053-7670-32 P9045

ALBUMINAR 25% 50 ML CSL BEHRING 00053-7680-32 P9047 100 ML 00053-7680-33 P9047

ALBURX 5% 250 ML CSL BEHRING 44206-0310-25 P9045 500 ML 44206-0310-50 P9045

ALBURX 25% 50 ML CSL BEHRING 44206-0251-05 P9047 100 ML 44206-0251-10 P9047

ALBUTEIN 5% 250 ML GRIFOLS 68516-5214-01 P9045 500 ML 68516-5214-02 P9045

ALBUTEIN 25% 50 ML GRIFOLS 68516-5216-01 P9047 100 ML 68516-5216-02 P9047

ALBUMIN 5% 250 ML OCTAPHARMA 67467-0623-02 P9045 250 ML 68209-0623-02 P9045 500 ML 68209-0623-03 P9045 500 ML 67467-0623-03 P9045

ALBUMIN 25% 50 ML OCTAPHARMA 67467-0643-01 P9047 50 ML 68209-0643-01 P9047 100 ML 67467-0643-02 P9047 100 ML 68209-0643-02 P9047

BUMINATE 5% 500 ML BAXALTA 00944-0491-02 P9045

BUMINATE 25% 20 ML BAXALTA 00944-0490-01 P9046 50 ML 00944-0490-02 P9047

FLEXBUMIN 5% 250 ML BAXALTA 00944-0495-05 P9047

FLEXBUMIN 25% 50 ML BAXALTA 00944-0493-01 P9047 100 ML 00944-0493-02 P9047

KEDBUMIN 25% 50 ML KEDRION 76179-0025-01 P9047 100 ML 76179-0025-04 P9047

PLASBUMIN 5% 50 ML GRIFOLS 13533-0685-20 P9041 250 ML 13533-0685-25 P9045

PLASBUMIN 25% 20 ML GRIFOLS 13533-0684-16 P9046 50 ML 13533-0684-20 P9047 100 ML 13533-0684-71 —

PLASBUMIN AFP 5% 50 ML GRIFOLS 13533-0690-02 — 250 ML 13533-0690-25 —

PLASBUMIN AFP 25% 20 ML GRIFOLS 13533-0692-16 — 50 ML 13533-0692-20 — 100 ML 13533-0692-71 —

PLASMANATE 5% (PPF) 50 ML PPF GRIFOLS 13533-0613-20 P9043 250 ML PPF 13533-0613-25 P9043

Albumin / Plasma Protein Fraction


*All codes should be verified between the provider and the payer.TO ORDER (800) 843-7477 | Fax (800) 418-4333 | www.FFFenterprises.com | www.MyFluVaccine.com | biosupply.fffenterprises.com

Public Health Services 340B pricing available.340B

340B

340B

340B

340B

340B

340B

340B

340B

340B

340B

340B

13

COAGUALATIONIM

MUNE

GLOBULINSHYPERIM

MUNES


OTHERVACCINES

ALBUMIN / PLASM

APROTEIN FRACTION

SPECIALTY& ONCOLOGY





ONCOLOGY (GENERICS)CLOLAR 20 MG/ML VIAL SANOFI AVENTIS 58468-0100-01 J9027GEMCITABINE** 200 MG SUN PHARMA 47335-0153-40 J9201 1 GM 47335-0154-40 J9201ONDANSETRON INJECTION** 4 MG/2 ML 25-PK HERITAGE PHARMA 23155-0196-43 J2405OXALIPLATIN** 50 MG/10 ML SDV SUN PHARMA 47335-0046-40 J9263 100 MG/20 ML 47335-0047-40 J9263ZALTRAP 100 MG/4 ML VIAL SANOFI AVENTIS 00024-5840-01 J9400 200 MG/ 8 ML VIAL 00024-5841-01 J9400ZOLINZA 100 MG ORAL CAPSULE MERCK 00006-0568-40 J8999

Oncology

Continued


SPECIALTY BIOPHARMACEUTICALS AND PHARMACEUTICALSACTIVASE 50 MG/50 ML VIAL GENENTECH 50242-0044-13 J2997 100 MG/100 ML VIAL 50242-0085-27 J2997

AMPICILLIN/SULBACTAM** 3 GM 10/PK AURO MEDICS 55150-0117-20 J0295ATRYN 525 IU VIAL REVO BIOLOGICS 42976-0121-01 J7196 1750 IU VIAL 42976-0121-02 J7196BERINERT 500 IU VIAL CSL BEHRING 63833-0825-02 J0597CROFAB 2 VIAL PK BTG INTERNATIONAL 50633-0110-12 J0840CUBICIN 500 MG SDV/10-PK MERCK 67919-0011-01 J0878DIGIFAB 40 MG VIAL BTG INTERNATIONAL 50633-0120-11 J1162FOLLISTIM AQ 75 IU SDV MERCK 00052-0308-02 J3490 300 IU CARTRIDGE 00052-0313-01 J3490 600 IU CARTRIDGE 00052-0316-01 J3490 900 IU CARTRIDGE 00052-0326-01 J3490FUROSEMIDE** 20 MG/2 ML 25-PK HERITAGE PHARMA 23155-0521-41 J1940 40 MG/4 ML 25-PK 23155-0521-42 J1940 100 MG/10 ML 25-PK 23155-0521-44 J1940GANIRELIX ACETATE 250 MCG/0.5 ML PFS MERCK 00052-0301-51 S0132HEMABATE 1 ML VIAL/10-PK PFIZER 00009-0856-08 J3490INTEGRILIN 75 MG/ML 100 ML VIAL MERCK 00085-1136-01 J1327 2 MG/ML 10 ML VIAL 00085-1177-01 J1327 2 MG/ML 100 ML VIAL 00085-1177-02 J1327MEROPENEM** 20 ML/500 MG 25/PK FRESENIUS KABI 63323-0507-20 J2185 30 ML/1 GM 25/PK 63323-0508-30 J2185 MIACALCIN 2 ML MDV MYLAN INSTITUTIONAL 54766-0149-23 J0630MOZOBIL 20 MG/1.2 ML VIAL SANOFI AVENTIS 58468-0140-01 J2562NAFCILLIN** 1 GM VIAL-10PK AURO MEDICS 55150-0122-15 S0032 2 GM VIAL-10PK 55150-0123-15 S0032 10 GM SDV 55150-0124-99 S0032OXACILLIN** 1 GM VIAL-10PK AURO MEDICS 55150-0127-15 TBD 2 GM VIAL-10PK 55150-0128-24 TBD 10 GM SDV 55150-0129-99 TBDSIVEXTRO TEDIZOLID PHOSPHATE 200 MG IV VIALS X 6 MERCK 67919-0041-02 P0300 200 MG IV VIALS X 10 67919-0040-01 P0300 200 MG IV VIALS X 30 67919-0041-01 P0300 THROMBATE III 500 IU VIAL GRIFOLS 13533-0603-20 J7197TNKASE 50 MG VIAL GENENTECH 50242-0120-01 J3101ZERBAXA 1.5 GM/10-VL MERCK 67919-0030-01 J3490/C9452

Specialty Biopharmaceuticals and Pharmaceuticals


VIPc

VIPc

VIPcVIPc

VIPc

VIPc

VIPc

VIPc340B

VIPc340B

340B


14


Manufacturer NDC# Code*

O J9027

G 47335-0154-40 J9201O

47335-0047-40 J9263Z J9400 00024-5841-01 J9400Z J8999

O

50242-0085-27 J2997

J7196

42976-0121-02 J7196B J0597C J0840C J0878D J1162F 00052-0313-01 J3490 00052-0316-01 J3490 00052-0326-01 J3490F 23155-0521-42 J1940 23155-0521-44 J1940G S0132H J3490I J1327 00085-1177-01 J1327 00085-1177-02 J1327M 63323-0508-30 J2185

J2562

N 55150-0123-15 S0032 55150-0124-99 S0032O 55150-0128-24 TBD 55150-0129-99 TBDS 67919-0040-01 P0300 67919-0041-01 P0300 T J7197T

MERCK 67919-0030-01 J

www.MyFluVaccine.com | biosupply.fffenterprises.com

V

P


Generic Injectables Product Size Manufacturer NDC# Code*

GENERIC INJECTABLESCIDOFOVIR** 375 MG HERITAGE PHARMA 23155-0216-31 J0740ENOXAPARIN** 30 MG/0.3 ML TEVA PHARMA 00703-8530-23 J1650 60 MG/0.6 ML 00703-8560-23 J1650 80 MG/0.8 ML 00703-8680-23 J1650 120 MG/0.8 ML 00703-8610-23 J1650HYDRALAZINE** 20 MG/ML 25-PK FRESENIUS KABI 63323-0614-01 J0360LEVETIRACETAM** 500 MG/5 ML SUN PHARMA 62756-0513-44 TBD

PIPERACILLIN & TAZOBACTAM** 2.25 GM 10-PK FRESENIUS KABI 63323-0309-20 J2543 3.375 GM 10-PK 63323-0300-30 J2543 4.5 GM 10-PK 63323-0320-50 J2543PROCHLORPERAZINE EDISYLATE** 2 ML 10 MG VL 10-BX HERITAGE PHARMA 23155-0294-42 TBDVANCOMYCIN** 10 GM 1-PK FRESENIUS KABI 63323-0314-61 J3370 1 GM 10-PK 63323-0284-20 J3370 500 MG 25-PK 63323-0221-10 J3370 5 GM SDV 1-PK 63323-0295-61 J3370VASOPRESIN** 20 UNITS/ML FRESENIUS KABI 63323-0302-01 TBDVECURONIUM BROMIDE** 10 MG SUN PHARMA 47335-0391-44 TBD

ONCOLOGY (BIOSIMILARS)ZARXIO** 300 MCG/0.5 ML PFS SANDOZ 61314-0304-01 TBD 300 MCG/0.5 ML PFS 10-BX 61314-0304-10 TBD 480 MCG/0.8 ML PFS 61314-0312-01 TBD 480 MCG/0.8 ML PFS 10-BX 61314-0312-10 TBD


* All codes should be verified between the provider and the payer. ** Call for eligibility through your GPO affiliation.

Surgical Sealants Product Size Manufacturer NDC# Code*

SURGICAL SEALANT GEL COSEAL 2 ML BAXTER BIOSCIENCE 01376-5404-61 — 4 ML 01376-5404-62 — 8 ML 01376-5404-63 —HEMOSTATIC MATRIX FLOSEAL 5 ML BAXTER BIOSCIENCE 08541-2096-10 — 10 ML 08541-2096-12 —FIBRIN SEALANT TOPICAL TISSEEL VHSD KIT 2 ML BAXTER BIOSCIENCE 00944-4301-02 J3590/C9399 VHSD KIT 4 ML 00944-4302-04 J3590/C9399 VHSD KIT 10 ML 00944-4303-10 J3590/C9399 2 ML VHSD VALUPAK 00944-4201-03 J3590/C9399 4 ML VHSD VALUPAK 00944-4211-04 J3590/C9399 10 ML VHSD VALUPAK 00944-4212-10 J3590/C9399FIBRIN SEALANT FROZENARTISS 2 ML BAXTER BIOSCIENCE 00944-8503-02 — 4 ML 00944-8503-04 — 10 ML 00944-8503-10 —TISSEEL 2 ML BAXTER BIOSCIENCE 00944-8402-02 — 4 ML 00944-8402-04 — 10 ML 00944-8402-10 —


Oncology (CONTINUED)

15

COAGUALATIONIM

MUNE

GLOBULINSHYPERIM

MUNES


OTHERVACCINES

ALBUMIN / PLASM

APROTEIN FRACTION

SPECIALTY& ONCOLOGY



M

MissionHelping

n®g Healthcare Care

e serve.

life for the patients we

http://www.fffenterprises.com/

Experie

ence

Experie more than

We are proud of ou

ence n 100 million lives that we’ve protected.

ree years and ur 27 counterfeit-f

AMBIVIG . Formula ® ®

. ated to insPIre

Enabling More Days to Ld nts missed that PI patieewtal trial shooPiv

deatrleoll teAM is wBIVIG

– s infuractions pe reseref adv oe ratThe6%7ns at 0.0actio resereadv 1

–

ead a Normal Lifelr schook oorar of weys/yd 2.3 da 1

suiorf se oeat1% with a rd at 0.09elatn calcuen has beio

2

2

tep Ahead in IVIGA S *

Delivering Safety That Mattersalsnt seevid-erpeamT

AMBIVIG ®

2

1

https://biosupply.fffenterprises.com/bivigam-5gm-50ml-human-ivig.html?utm_source=BSTQ_2015-10&utm_medium=AD&utm_campaign=Prod&utm_term=Bivigam

AM BIVIGUS plasm

wo Vial Sizes in T Two Vial Sizes

A fromM is manufactured in the US SA from ma for US providers and patients.

ge, ced anadve aclud inr sculaag vellindw n

y occureath ma dl ae rentcud an action

isk of t rts atien paor Fe rsuble. Encticaae prt

ts at atien p viscosity in

vailable i AAvailable in T

730-6502-1NDC: 59

2

730-6503-1NDC: 5900 mL vialn contains a 1otA car

arning:WWarning: uline globnr with immuy occuombosis ma Thrs ditionle conlabgucoayper immobilization, hgedolonproctisk far rlascuavrdiod canviscosity aeryps, hertcatheo envatrn Iuline Globnmmu of Itionaistrminwith the ad

g IGIVeceivints rtien paly ine common more occurilurfaismine, adl failura ren, orctionnl dysfuenaosis, rombthrs ationistrdminore aefts btien pa intionydrae htuadeqa

.or viscosityisk fr or cation f for comorm See full Prescribing Inf form

Visit

. ences: 1erefR ®2.

com bivigam. to learn more today!

y s maorctisk faAM. Rding BIVIGclucts, inodu) prous (IGIVenvtra inns, inogense of estrombosis, the ul threriatr aous oreny of vors, a hist

ddosis, anhreptic ne, osmorilul faae rent, acuctionnysful daens. Rorcysfunl daents. Rtien paosedisped prcts inodu) pr) (IGIVmanus (Hu

ose. sucrintat conooes nAM dIGose. BIVcrg suinintacts conodu pr V V pr rafusiond innded aecommenimum dose rt the minAM aIGer BIVst

lood assess bdombosis anoms of thrt sympdns aor signor fits. Monarning.ed wxe bo oxtple om

arn more today!

l.v Clin Immunoet RExperrt R

https://biosupply.fffenterprises.com/bivigam-5gm-50ml-human-ivig.html?utm_source=BSTQ_2015-10&utm_medium=AD&utm_campaign=Prod&utm_term=Bivigamhttps://biosupply.fffenterprises.com/bivigam-5gm-50ml-human-ivig.html?utm_source=BSTQ_2015-10&utm_medium=AD&utm_campaign=Prod&utm_term=Bivigamhttps://biosupply.fffenterprises.com/bivigam-10gm-100ml-human-ivig.html?utm_source=BSTQ_2015-10&utm_medium=AD&utm_campaign=Prod&utm_term=Bivigamhttp://www.biotestpharma.com/

BIVIGAM® [Immune Globulin Intravenous (Human), 10% Liquid] Rx onlyBrief summary: Consult the full Prescribing Information for complete product information WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE Thrombosis may occur with immune globulin (IGIV) products, including BIVIGAM. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, a history of venous or arterial thrombosis, the use of estrogens, indwelling central vascular catheters, hyperviscosity and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. Use of Immune Globulin Intravenous (IGIV) products, particularly those containing sucrose, has been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death. Patients at risk of acute renal failure include those with any degree of pre-existing renal insufficiency, diabetes mellitus, advanced age (above 65 years of age), volume depletion, sepsis, paraproteinemia, or receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. BIVIGAM does not contain sucrose. For patients at risk of thrombosis, renal dysfunction, or renal failure, administer BIVIGAM at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.Indication and Usage: BIVIGAM is an Immune Globulin Intravenous (Human), 10% Liquid, indicated for the treatment of primary humoral immunodeficiency (PI). Contraindications: BIVIGAM is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin. BIVIGAM is contraindicated in IgA deficiency patients with antibodies to IgA and a history of hypersensitivity. Warnings and Precautions: Thrombosis: Thrombosis may occur following treatment with IGIV products, including BIVIGAM. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. For patients at risk of thrombosis, administer BIVIGAM at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. Hypersensitivity: Severe hypersensitivity reactions may occur with IGIV products, including BIVIGAM. In case of hypersensitivity, discontinue BIVIGAM infusion immediately and institute appropriate treatment. Medications such as epinephrine should be available for immediate treatment of acute hypersensitivity reactions.

. Patients with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. BIVIGAM is contraindicated in IgA deficient patients with antibodies against IgA and a history of hypersensitivity reaction. Acute Renal Dysfunction and Acute Renal Failure: Acute renal dysfunction/failure, osmotic nephrosis, and death may occur upon use of human IGIV products. Ensure that patients are not volume depleted before administering BIVIGAM. Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk of developing acute renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of BIVIGAM and at appropriate intervals thereafter. If renal function deteriorates, consider discontinuing BIVIGAM. In patients who are at risk of developing renal dysfunction, because of pre-existing renal insufficiency or predisposition to acute renal failure (such as diabetes mellitus, hypovolemia, overweight, use of concomitant nephrotoxic medicinal products or age of >65 years), administer BIVIGAM at the minimum infusion rate practicable. Hyperproteinemia, Increased Serum Viscosity, and Hyponatremia: Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in patients receiving IGIV therapy, including BIVIGAM. It is critical to clinically distinguish true hyponatremia from a pseudohyponatremia that is associated with or causally related to hyperproteinemia with concomitant decreased calculated serum osmolality or elevated osmolar gap, because treatment aimed at decreasing serum free water in patients with pseudohyponatremia may lead to volume depletion, a further increase in serum viscosity, and a possible predisposition to thrombotic events. Aseptic Meningitis Syndrome (AMS): AMS may occur infrequently with IGIV treatments including BIVIGAM. AMS usually begins within several hours to 2 days following IGIV treatment. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae. AMS is characterized by the following signs and symptoms: severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea, and vomiting.Cerebrospinal fluid (CSF) studies frequently reveal pleocytosis up to several thousand cells per cubic millimeter, predominantly from the granulocytic series, and elevated protein levels up to several hundred mg/dL, but negative culture results. Conduct a thorough neurological examination on patients exhibiting such signs and symptoms, including CSF studies, to rule out other causes of meningitis. AMS may occur more frequently in association with high doses (2 g/kg) and/or rapid infusion of IGIV. Hemolysis: IGIV products, including BIVIGAM, may contain blood group antibodies that can act as hemolysins and induce in vivo coating of red blood cells (RBCs) with immunoglobulin, causing a positive direct antiglobulin reaction and, rarely, hemolysis. Delayed hemolytic anemia can develop subsequent to IGIV therapy due to enhanced RBC sequestration,13 and acute hemolysis, consistent with intravascular hemolysis, has been reported. Monitor patients for clinical signs and symptoms of hemolysis. If these are present after BIVIGAM infusion, perform appropriate confirmatory laboratory testing. If transfusion is indicated for patients who develop hemolysis with clinically compromising anemia after receiving IGIV, perform adequate cross-matching to avoid exacerbating on-going hemolysis. Transfusion-Related Acute Lung Injury (TRALI): Noncardiogenic pulmonary edema may occur in patients following IGIV treatment including BIVIGAM. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever. Symptoms typically appear within 1 to 6 hours following treatment. Monitor patients for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of anti- . TRALI may be managed using oxygen therapy with adequate ventilatory support. Transmissible

Infectious Agents: Because BIVIGAM is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases or CJD have been associated with the use of BIVIGAM. All infections suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Biotest Pharmaceuticals Corporation at 1-800-458-4244. Before prescribing BIVIGAM, the physician should discuss the risks and benefits of its use with the patient. Monitoring Laboratory Tests: Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk of developing acute renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of BIVIGAM and at appropriate intervals thereafter. Because of the potentially increased risk of thrombosis with IGIV treatment, consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. If signs and/or symptoms of hemolysis are present after an infusion of BIVIGAM, perform appropriate laboratory testing for confirmation. If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the

Interference with Laboratory Tests: After infusion of immunoglobulin, the transitory rise of the various passively transferred antibodies in the

sitive serological testing results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g., A,

ADVERSE REACTIONS: Serious adverse reactions observed in clinical trial subjects receiving BIVIGAM were vomiting and dehydration in one subject. The most common

fatigue, infusion site reaction, nausea, sinusitis, blood pressure increased, diarrhea, dizziness, and lethargy. Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials cannot be directly compared to rates in the clinical trials of another product and may not reflect the rates observed in clinical practice. In a multicenter, open-label, non-randomized clinical trial, 63 subjects with PI, on regular IGIV replacement therapy, received doses of BIVIGAM ranging from 254 to 1029 mg/kg (median dose 462.8 mg/kg) every 3 weeks or 4 weeks for up to 12 months (mean 317.3 days; range 66 – 386 days). The use of pre-medication was discouraged; however, if subjects required pre-medication (antipyretic, antihistamine, or antiemetic agent) for recurrent reactions to immune globulins, they were allowed to continue those medications for this trial. Of the 746 infusions administered, 41 (65%) subjects received premedication prior to 415 (56%) infusions. Fifty-nine subjects (94%) had an adverse reaction at some time during the study. The proportion of subjects who had at least one adverse reaction was the same for both the 3- and 4-week cycles. The most common adverse reactions observed in this clinical trial were headache (32 subjects, 51%), sinusitis (24 subjects, 38%), fatigue (18 subjects, 29%), upper respiratory tract infection (16 subjects, 25%), diarrhea (13 subjects, 21%), cough (14 subjects, 22%), bronchitis (12 subjects, 19%), pyrexia (12 subjects, 19%), and nausea (9 subjects, 14%). Adverse reactions (ARs) are those occurring during or within 72 hours after the end of an infusion. In this study, the upper bound of the 1-sided 95% confidence interval for the proportion of BIVIGAM infusions with one or more temporally associated adverse reactions was 31%. The total number of adverse reactions was 431 (a rate of 0.58 ARs per infusion). Seven subjects (11.1%) experienced 11 serious ARs. Two of these were related serious Table: Adverse Reactions (ARs) (within 72 hours after the end of a BIVIGAM infusion) in

aSymptoms occurring under pre-existing fibromyalgia

ARs (vomiting and dehydration) that occurred in one subject. One subject withdrew from the study due to ARs related to BIVIGAM (lethargy, headache, tachycardia and pruritus). All 63

During the study, no subjects showed clinical evidence of hemolytic anemia. No cases of transmission of viral diseases or CJD have been associated with the use of BIVIGAM. During the clinical trial no subjects tested positive for infection due to human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). There was a single positive finding for parvovirus (B19 virus) during the study. This subject came in contact with acute B19 virus from working at a school greeting children where a child was reported to have symptomatic Fifth's disease. There was no cluster (no other cases in other subjects) of B19 virus transmission with the IGIV batch concerned.DRUG INTERACTIONS Live Virus Vaccines Immunoglobulin administration may transiently impair the efficacy of live attenuated virus vaccines such as measles, mumps, rubella, and varicella because the continued presence of high levels of passively acquired antibody may interfere with an active antibody response. The immunizing physician should be informed of recent therapy with BIVIGAM so that appropriate measures may be taken.

ARsNo. Subjects

Reporting ARs(% of Subjects)[n=63]

No. Infusions With ARs(% of Infusions)[n=746]

Headache 27 (43%) 115 (15.4%)Fatigue 15 (24%) 59 (7.9%)Infusion Site Reaction 5 (8%) 5 (0.7%)Nausea 5 (8%) 8 (1.1%)Sinusitis 5 (8%) 5 (0.7%)Blood Pressure Increased 4 (6%) 5 (0.7%)Diarrhea 4 (6%) 4 (0.5%)Dizziness 4 (6%) 4 (0.5%)Lethargy 4 (6%) 4 (0.5%)Back Pain 3 (5%) 3 (0.4%)Blood Pressure Diastolic Decreased

3 (5%) 5 (0.7%)

Fibromyalgiaa 3 (5%) 17 (2.3%)Migraine 3 (5%) 8 (1.1%)Myalgia 3 (5%) 4 (0.5%)Pharyngolaryngeal Pain 3 (5%) 3 (0.4%)

Dec-2013, [10760-90-IGG-032013_R01]

Th

roduPe

ucts you

eed n

d

yowhen

eednu o

d them.

Fl V

Hype

Coag

Imm

Flu V

i V

esunerimm

gulation Products

e Globulinsunm

eaccin V Vaccin

Spec

Othe

Albumin

Hype

cialty Biologicals

andes acciner V

umin

esunerimm

Inc©2015 FFF Enterprises, . ente.FFFwww(800

erprises.com) 843-7477

https://biosupply.fffenterprises.com/product-cataloghttp://www.fffenterprises.com

f

R o

Visit NovoeightPro.com today to learn more.

N

a h

T

T

f

S

6

Indications and UsageNovoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® is not indicated for the treatment of von Willebrand disease.

Important Safety InformationDo not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Development of activity-neutralizing antibodies (inhibitors) may occur. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration.

The most frequently reported adverse reactions (≥0.5%) were injection site reactions, increased hepatic enzymes, and pyrexia.

1

FFF Enterprises •

All rights reserved. 0315-00026032-1 April 2015

https://biosupply.fffenterprises.com/novoeight-250-unit.html?utm_source=BSTQ_2015-10&utm_medium=AD&utm_campaign=Prod&utm_term=Bivigamhttp://www.novoeightpro.com/

Multiple dose strengths help infuse patients with fewer vials1

Novoeight® — a proven safe and effective treatment for hospital patients with hemophilia A1

Indicated for use in adults and children with hemophilia A for:

• Control and prevention of bleeding

• Perioperative management

• Routine prophylaxis to prevent or reduce the frequency of bleeding episodes

Novoeight® (Antihemophilic Factor [Recombinant]) — an evolution in treatment for hospital patients with hemophilia A

Please see Prescribing Information for complete storage instructions.

36˚F to 46˚F

30

6

USABILITY

FLEXIBILITY

STORAGE

VALUE

UP TO MONTHS

refrigerated storage1

VIAL SIZESRoom temperature storage

FOR 12 MONTHS

UP TO 86 FO after reconstitution1

• Longest of all recombinant factor VIII products1-7

4-HOUR STORAGE TIME

Please see Brief Summary of Prescribing Information on the adjacent page.

References: 1. Novoeight® [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; 2014. 2. ADVATE™ [package insert]. Westlake Village, CA: Baxter Healthcare Corp.; 2014. 3. ELOCTATE® [package insert]. Cambridge, MA: Biogen Idec Inc.; 2014. 4. Helixate® FS [package insert]. Whippany, NJ: Bayer HealthCare LLC; 2014. 5. Kogenate® FS [package insert]. Tarrytown, NY: Bayer HealthCare LLC; 2014. 6. RECOMBINATE™ [package insert]. Westlake Village, CA: Baxter Healthcare Corp.; 2014. 7. XYNTHA® [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc., 2014.

I

a

i

1Facilitates quick reconstitution and consistent preparation of treatment

SYRINGE4 mL pre-�lled diluent

Talk to your authorized distributor to learn more about Novoeight® or visit NovoeightPro.com for answers and resources. FFF Enterprises • 1-800-843-7477

© 2015 Novo Nordisk All rights reserved. 0315-00026032-1 April 2015

Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.

Novoeight® is a registered trademark of Novo Nordisk Health Care AG.

1 9 2:12 PM

https://biosupply.fffenterprises.com/novoeight-250-unit.html?utm_source=BSTQ_2015-10&utm_medium=AD&utm_campaign=Prod&utm_term=Bivigamhttps://biosupply.fffenterprises.com/novoeight-250-unit.html?utm_source=BSTQ_2015-10&utm_medium=AD&utm_campaign=Prod&utm_term=Bivigamhttps://biosupply.fffenterprises.com/catalogsearch/result/?q=novoeight?utm_source=BSTQ_2015-10&utm_medium=AD&utm_campaign=Prod&utm_term=Bivigamhttps://biosupply.fffenterprises.com/catalogsearch/result/?q=novoeight?utm_source=BSTQ_2015-10&utm_medium=AD&utm_campaign=Prod&utm_term=Bivigamhttp://www.novoeightpro.com/https://biosupply.fffenterprises.com/novoeight-250-unit.html?utm_source=BSTQ_2015-10&utm_medium=AD&utm_campaign=Prod&utm_term=Bivigam

Novoeight®, Antihemophilic Factor (Recombinant)

Rx Only

BRIEF SUMMARY: Please consult package insert for full prescribing information

INDICATIONS AND USAGE: Novoeight®, Antihemophilic Factor (Recombinant), is indicated for use in adults and children with hemophilia A (congenital factor VIII de�ciency or classic hemophilia) for: control and prevention of bleeding episodes; Perioperative management; routine prophylaxis to prevent or reduce the frequency of bleeding episodes. Novoeight® is not indicated for the treatment of von Willebrand disease.

CONTRAINDICATIONS: Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components (including traces of hamster proteins).

WARNINGS AND PRECAUTIONS: Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis, are possible with Novoeight®. Novoeight® contains trace amounts of hamster proteins. Patients treated with this product may develop hypersensitivity to these non-human mammalian proteins. Early signs of hypersensitivity reactions that can progress to anaphylaxis include angioedema, chest tightness, dyspnea, wheezing, urticaria, and pruritus. Immediately discontinue administration and initiate appropriate treatment if allergic- or anaphylactic-type reactions occur. Neutralizing Antibodies: Formation of neutralizing antibodies (inhibitors) to factor VIII can occur following administration of Novoeight®. Monitor all patients for the development of inhibitors by appropriate clinical observation and laboratory testing. If the expected plasma levels of factor VIII activity are not attained, or if bleeding is not controlled with an appropriate dose, perform testing for factor VIII inhibitors. Monitoring Laboratory Tests: Monitor plasma factor VIII activity levels by the one-stage clotting assay or the chromogenic substrate assay to con�rm that adequate factor VIII levels have been achieved and maintained, when clinically indicated. Perform assay to determine if factor VIII inhibitor is present if expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with the expected dose of Novoeight®. Determine inhibitor levels in Bethesda Units.

ADVERSE REACTIONS: The most frequently reported adverse reactions (≥ 0.5%) were injection site reactions, increased hepatic enzymes, and pyrexia. Clinical Trials Experience: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not re�ect the rates observed in clinical practice. During the clinical development of Novoeight®, 214 male previously treated patients (PTPs; exposed to a factor VIII-containing product for ≥150 days) with severe hemophilia A (factor VIII level ≤1%) received at least one dose of Novoeight® as part of either routine prophylaxis, on-demand treatment of bleeding episodes, perioperative

management of major and minor surgical, dental, or other invasive procedures, or pharmacokinetic evaluation of Novoeight®. Thirty-one subjects (14%) were

distributes evious st pr

passive RF erified Inv V

s – leaving you ee to focus i

fr torage location n and conditi

a FID technology y to track, tra g ogr Consig –ram ventory Pr

e. s on patient carod e pr ion of the critical-car

ace, and verify the moment of use, statuses gnment (VIPc)™

ducts FFF t of use,

e-of-the-art,

Eliminahighhi h va

Increase

high-va

tlue critical productsoducts

ces carrying cl i i l

osts ofd

es visibility of pro oduct

lue critical pr

Monit,

ors remotely priquantityquantity l, loca, loca i dtion andtion and

temperature

r d

oduct d

iseprert©2015 FFF En

(800) 84 .nc, Ies

43-7477 x1142 | [email protected]

[email protected]

http://www.fffenterprises.com/services/verified-inventory-program.htmlhttp://www.fffenterprises.com/services/verified-inventory-program.htmlmailto:[email protected]

ount on FFF's securC»Y DELIVER AFELY WE S

om Choose fr»ANTITY OU PICK THE QUY

en vonC»TE AT Y DOU PICK THE DELIVERY

egeed Channel Intante supply channel with Guar ecur

oductsolio of proad portf a br

)se(tery dat delivOUR bese Yniently secur

grity™

O U P Y

O ORDER T

O U T E • YA I C K T H E D

7747.843.om | 800c.cineac | MyFluV

A P R O G R A M O F F F F E N T E R P R I S E S

A N T I T Y • W E D E L I V E R P I C K T H E Q U

v 0515e7 Rerprises, Inc. FL3315 FFF Ent©20

http://www.myfluvaccine.com/Login.aspxhttp://www.myfluvaccine.com/

AEAHGNNINALP

SIDA

RPOWEPSUR OUYAEAHGNNINALP

OPTECINCAVULFRUOYESCHOO

. REWSIDA

:NTIO

tion.cInje

.lasanaIntr

-.ladermaIntr

.

j

||

http://www.myfluvaccine.com/http://www.myfluvaccine.com/http://www.myfluvaccine.com/

28 FL21

5 101

5

h24h

enterprises.com .FFF(800) 843-7477 | www

s e n hyperimmune i c a gllobulobulinsigim v flu g i … · 2015. 10. 23. · the products you s c...

Documents